{"nctId":"NCT01236560","briefTitle":"Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma","startDateStruct":{"date":"2011-01-26","type":"ACTUAL"},"conditions":["Brain Stem Glioma","Cerebral Astrocytoma","Childhood Cerebellar Anaplastic Astrocytoma","Childhood Cerebral Anaplastic Astrocytoma","Childhood Spinal Cord Neoplasm"],"count":101,"armGroups":[{"label":"Arm I (vorinostat, Phase II Arm A)","type":"EXPERIMENTAL","interventionNames":["Biological: Bevacizumab","Drug: Temozolomide","Drug: Vorinostat"]},{"label":"Arm II (temozolomide, Phase II Arm B)","type":"EXPERIMENTAL","interventionNames":["Biological: Bevacizumab","Drug: Temozolomide"]},{"label":"Arm III (Bevacizumab, Phase II Arm)","type":"EXPERIMENTAL","interventionNames":["Biological: Bevacizumab","Drug: Temozolomide"]},{"label":"Arm IV (temozolomide, Phase 3 Arm B)","type":"EXPERIMENTAL","interventionNames":["Biological: Bevacizumab","Drug: Temozolomide"]},{"label":"Arm V (vorinostat/bevacizumab, Phase 3, Chemoradiotherapy)","type":"EXPERIMENTAL","interventionNames":["Biological: Bevacizumab","Drug: Temozolomide","Drug: Vorinostat"]},{"label":"Feasibility (vorinostat)","type":"EXPERIMENTAL","interventionNames":["Biological: Bevacizumab","Drug: Temozolomide","Drug: Vorinostat"]}],"interventions":[{"name":"Bevacizumab","otherNames":["ABP 215","Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF Monoclonal Antibody SIBP04","Anti-VEGF rhuMAb","Avastin","BAT 1706","BAT-1706","BAT1706","BAT1706 Biosimilar","Bevacizumab awwb","Bevacizumab Biosimilar ABP 215","Bevacizumab Biosimilar BAT1706","Bevacizumab Biosimilar BEVZ92","Bevacizumab Biosimilar BI 695502","Bevacizumab Biosimilar CBT 124","Bevacizumab Biosimilar CT-P16","Bevacizumab Biosimilar FKB238","Bevacizumab Biosimilar GB-222","Bevacizumab Biosimilar HD204","Bevacizumab Biosimilar HLX04","Bevacizumab Biosimilar IBI305","Bevacizumab Biosimilar LY01008","Bevacizumab Biosimilar MIL60","Bevacizumab Biosimilar Mvasi","Bevacizumab Biosimilar MYL-1402O","Bevacizumab Biosimilar QL 1101","Bevacizumab Biosimilar QL1101","Bevacizumab Biosimilar RPH-001","Bevacizumab Biosimilar SCT501","Bevacizumab Biosimilar Zirabev","Bevacizumab-adcd","Bevacizumab-awwb","Bevacizumab-bvzr","BP102","BP102 Biosimilar","CT-P16","HD204","Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","Mvasi","MYL-1402O","QL1101","Recombinant Humanized Anti-VEGF Monoclonal Antibody","rhuMab-VEGF","SCT501","SIBP 04","SIBP-04","SIBP04","Vegzelma","Zirabev"]},{"name":"Temozolomide","otherNames":["CCRG-81045","Gliotem","Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-","M & B 39831","M and B 39831","Methazolastone","RP-46161","SCH 52365","Temcad","Temizole","Temodal","Temodar","Temomedac","TMZ"]},{"name":"Vorinostat","otherNames":["L-001079038","MSK-390","SAHA","Suberanilohydroxamic Acid","Suberoylanilide Hydroxamic Acid","Zolinza"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Newly diagnosed high-grade glioma\n\n  * Anaplastic astrocytoma\n  * Glioblastomamultiforme\n  * Gliosarcoma\n  * Primary spinal cord malignant glioma allowed\n  * No oligodendroglioma oroligoastrocytoma\n* Patient must have histological verification of diagnosis\n\n  * No M+ disease (defined as evidence of neuraxis dissemination)\n  * No positive CSF cytology\n* ECOG performance status (PS) 0-2\n\n  * Karnofsky PS 50-100% (patients \\> 16 years of age)\n  * Lansky PS 50-100% (patients ≤ 16 years of age)\n* ANC ≥ 1,000/μL\n* Platelet count ≥ 100,000/μL\n* Hemoglobin ≥ 8.0 mg/dL (transfusion independent)\n* Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age and/or gender as follows:\n\n  * 0.4 mg/dL (1 month to \\< 6 months of age)\n  * 0.5 mg/dL (6 months to \\< 1 year of age)\n  * 0.6 mg/dL (1 to \\< 2 years of age)\n  * 0.8 mg/dL (2 to \\< 6 years of age)\n  * 1.0 mg/dL (6 to \\< 10 years of age)\n  * 1.2 mg/dL (10 to \\< 13 years of age)\n  * 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to \\< 16 years of age)\n  * 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)\n* Proteinuria \\< 2+ OR urine; protein ratio (UPC) ≤ 0.5\n\n  * If UPC \\> 0.5, a 24-hour urine protein should be obtained and level should be \\< 1,000 mg of protein\n* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* ALT \\< 2.5 times ULN\n* Serum albumin ≥ 2 g/dL\n* PT INR ≤ 1.5 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during all study therapy and for ≥ 6 months after completion of bevacizumab\n* Hypertension well controlled (≤ 95\\^th percentile for age and height if patient is ≤ 17years) by stable doses of medication allowed\n\n  * For patients \\> 17 years, systolic blood pressure (BP) ≤ 150 mm Hg or diastolic BP ≤ 100 mm Hg)\n* Seizure disorder allowed provided patient is well-controlled and on nonenzyme-inducing anticonvulsants\n* No history of myocardial infarction, severe or unstable angina, clinically significant peripheral vascular disease, ≥ grade 2 heart failure, or serious and inadequately controlled cardiac arrhythmia\n* No known bleeding diathesis or coagulopathy\n* No prior arterial thromboembolic events, including transient ischemic attacks orcerebrovascular accidents\n* No prior diagnosis of a deep venous thrombosis, including pulmonary embolism, and no known thrombophilic condition (e.g., protein S, protein C, antithrombin III deficiency, Factor V Leiden or Factor II G202'0A mutation, homocysteinemia, or antiphospholipid antibody syndrome)\n* No history of an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months\n* No serious or non-healing wound, ulcer, or bone fracture\n* No evidence of significant postoperative intracranial hemorrhage, defined as \\> 1 cm of blood on postoperative MRI scan (potentially in addition to the postoperative scan) obtained within the past 14days\n* No history of allergic reaction to Chinese hamster ovary cell products or other recombinanthuman antibodies\n* No more than 31 days since definitive surgery\n* Must not have received any prior chemotherapy, radiotherapy, immunotherapy, or bone marrow transplant\n* More than 7 days since major surgical procedure and recovered\n\n  * For patients scheduled to receive bevacizumab:\n\n    * More than 28 days since major procedure\n    * More than 14 days since intermediate procedure\n    * More than 7 days since minor procedure (lumbar picture or placement of PICC lines are not considered minor procedures)\n* No other current anti-cancer agents\n* No concurrent nonsteroidal anti-inflammatory medications known to inhibit platelet function or known to selectively inhibit cyclooxygenase activity\n* No concurrent enzyme inducing anticonvulsants\n* No concurrent HDAC inhibitors (e.g., valproic acid)\n* No concurrent anticoagulants including systemic thrombolytic agents, heparin, low molecular weight heparins, or warfarin except as required to maintain patency of pre-existing permanent vascular catheters or for prevention of thrombosis in the post-operative period","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Tolerated Dose (MTD) of Vorinostat","description":"The dose of vorinostat in mg/sq m/day to be administered with combination chemotherapy and radiation therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null}]}]}]},{"type":"PRIMARY","title":"Event-free Survival","description":"Time from enrollment to disease progression, diagnosis of a second malignant neoplasm, death or last follow-up, whichever occurs first. Disease progression is evaluated according to the COG criteria for measurement of brain tumors and is defined to be a ≥ 25% increase in the product of perpendicular diameters of ANY target lesion, taking as reference the smallest product observed since the start of treatment; OR the appearance of one or more new lesions, OR worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc) PLUS any increase in tumor cross-sectional area (or tumor volume).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"41.3","spread":null},{"groupId":"OG002","value":"59.3","spread":null},{"groupId":"OG003","value":"43.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Time from enrollment to death or last follow-up, whichever occurs first.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"82.2","spread":null},{"groupId":"OG002","value":"85.2","spread":null},{"groupId":"OG003","value":"67.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Disease Progression in Each Treatment Arm","description":"Cumulative incidence of progression where death from any cause prior to progression and diagnosis of a second malignant neoplasm prior to progression are considered competing events. Disease progression is evaluated according to the COG criteria for measurement of brain tumors and is defined to be a ≥ 25% increase in the product of perpendicular diameters of ANY target lesion, taking as reference the smallest product observed since the start of treatment; OR the appearance of one or more new lesions, OR worsening neurologic status not explained by causes unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, presumed post-therapy swelling etc) PLUS any increase in tumor cross-sectional area (or tumor volume).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":6},"commonTop":["Platelet count decreased","Neutrophil count decreased","White blood cell decreased","Lymphocyte count decreased","Headache"]}}}